Experimental study on the gene therapy of malignant glioma with antisense VEGF RNA
Tóm tắt
Objective: To study the effect of antisense VEGF RNA on rat C6 gliomas in vivo and find out the feasibility of antiangiogenesis therapy with antisense VEGF RNA for malignant gliomas. Methods: Parental rat C6 glioma cells and C6 cells transfected with antisense VEGF cDNA were implanted intracerebrally and subcutaneously into SD rats as control and transfected group. Rats bearing cerebral and subcutaneous C6 gliomas were treated with antisense VEGF cDNA as treated group and sense VEGF cDNA and empty vector as control of treated group. The general manifestation, survival time, MRI and histopathological changes of all rats were observed. The volume of subcutaneously implanted tumors was determined regularly.In situ hybridization and immunohistochemical staining were used for detection of VEGF gene expression of gliomas while PCNA immunostaining and TUNEL method for examination of proliferation activity and apoptosis of gliomas, respectively. Results: The survival of the rats in transfected and treated group was prolonged. There were two rats surviving over 90 d in the treated group and their tumors disappeared. The VEGF gene expression, the number of microvessels and the proliferation activity were decreased and a large amount of apoptotic cells could be found in cerebral and subcutaneous gliomas in treated and transfected groups. Conclusion: VEGF is one of the candidate genes for gene therapy of malignant gliomas. Antisense VEGF RNA combined with other therapies should be studied further for enhancing the therapeutic effect of malignant gliomas.
Tài liệu tham khảo
Lund EL, Spang-Thomsen M, Skovgaard-Poulsen H, et al. Tumor angiogenesis—a new therapeutic target in gliomas[J]. Acta Neurol Scand 1998; 97: 52.
Wesseling P, Ruiter DJ, Burger PC. Angiogenesis in brain tumors: pathological and clinical aspects[J]. J Neuro-oncol 1997; 32: 253.
Plate KH, Risau W. angiogenesis in malignant glioma[J]. Glia 1995; 15: 339.
Rosen L. Antiangiogenic strategies and agents in clinical trials[J]. The Oncologist 2000; 5(Suppl 1): 20.
Ferrara N, Houck K, Jakeman L, et al. Molecular and biological properties of the vascular endothelial growth fadtor family of proteins[J]. Endocrine Rev 1992; 13: 18.
Leon SP, Folkerth RD, Black PM. Microvessel density is a prognostic indicator for patients with astroglial brain tumors[J]. Cancer 1996; 77: 362.
Assimakopoulou M, Sotiropoulou-Bonikou G, Maraziotis T, et al. Microvessel density in brain tumors[J]. Anticancer Res 1997; 17: 4747.
Im SA, Kim JS, Gomez-Manzano C, et al. Inhibition of breast cancer growth in vivo by antiangiogenesis gene therapy with adenovirus mediated antisense VEGF[J]. Br J Cancer 2001; 84: 1252.
Shinkaruk S, Bayle M, Lain G, et al. Vascular endotherlial cell growth factor (VEGF), an emerging target for cancer therapy [J]. Curr Med Chem Anticancer Agents 2003; 3: 95.
Glade-Bender J, Kandel JJ, Yamashiro DJ. VEGF blocking therapy in the treatment of cancer[J] Expert Opin Biol Ther 2003; 3: 263.
Monley PW, Martiny-Baron G, Schlaeppi JM, et al. Therapies directed at vascular endothelial growth factor[J]. Expert Opin Invest Drugs 2002; 11:1715.
Dvorak HF. Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy[J]. J Clin Oncol 2002; 20: 4368.
Wang JZ, Pu PY, Huang Q, et al. The relationship among VEGF expression, proliferation activity and microvessel density in brain tumors (in Chinese)[J]. Chin J Nerv & Ment Dis 2000;26:93.
Pu PY, Liu XW, Liu AX, et al. Inhibitory effect of antisense epidermal growth factor receptor RNA on the proliferation of rat C6 glioma cellsin vitro andin vivo[J]. J Neurosurg 2000; 92: 132.
Millauer B, Shawver LK, Plate KH, et al. Glioblastoma growth inhibited in vivo by a dominant negative FLK-1 mutant[J]. Nature 1994; 367: 576.
Cheng SY, Huang HJS, Nagane M, et al. Suppression of glioblastoma angiogenicity and tumorigenicity by inhibition of endogenous expression of vascular endotherlial growth factor[J]. Proc Natl Acad Sci USA 1996; 93: 8502.
Im SA, Gomez-Manzano C, Fueyo J, et al. Antiangiogenesis treatment for gliomas: transfer of antisense vascular endothelial growth actor inhibits tumor growthin vivo[J]. Cancer Res 1999; 59: 895.
Fitzpatrick TE, Lash GE, Yanaihara A, et al. Inhibition of breast carcinoma and trophost cell invasiveness by vascular endotherlial growth factor[J]. Exp Cell Res 2003; 283: 2247.
Niethammer AG, Xiang R, Becker JC, et al. A DNA vaccine against VEGFR-2 prevent effective angiogenesis and inhibits tumor growth[J]. Nat Med 2002; 8: 1369.
Halin C, Niesnr U, Villani ME, et al. Tumor targeting properties of antibody-vascular endotherlial growth factor fusion protein[J]. Int J Cancer 2002; 102: 109.
Miao RQ, Agata J, Shao L, et al. Kallistain is a new inhibitor of angiogenesis and tumor growth[J]. Blood 2002; 100: 3245.
Wedge SR, Ogilvie DJ, Dukes M, et al. ZD6474 inhibits vascular endotherlial growth factor signaling, angiogenesis, and tumor growth following oral administration[J]. Cancer Res 2002; 62: 4645.
Hotz HG, Hines OJ, Hotz B, et al. Evaluation of vascular endotherlial growth factor blockade and matrix metalloproteinase inhibition as a combination therapy for experimental human pancreatic cancer[J]. J Gastrointest Surg 2003; 7: 220.
Takano S, Tsubio K, Matsumura A, et al. Anti-vascualr endothelial growth factor antibody and nimustine as combined therapy: Effects on tumor growth and angiogenesis in human glioblastoma xenografts[J]. Neuro-oncol 2003; 5: 1.